Hypothesis

Low pain tolerance reflects primed microglia in the central amygdala that drive NLRP3 inflammasome activation, releasing IL‑1β and caspase‑1 into the circulation. This peripheral inflammaging signal accelerates epigenetic aging independently of HPA‑axis activity.

Rationale

Chronic pain correlates with accelerated Horvath, PhenoAge and GrimAge clocks [PMC6710702][SAGE journals]. Central amygdala CRF neurons act as a pain switch that inhibits descending analgesia [PMC5658242]. CRF hyperactivity also sustains stress pathways that accelerate aging. Microglial priming in the amygdala is known to amplify CRF signaling and to trigger NLRP3 inflammasome assembly, leading to IL‑1β release [PMC5658242]. Fear extinction failure, which predicts neuropathic pain, is linked to basolateral amygdala hyperexcitability in aging and Alzheimer models [PMC6172937][PMC9239848]; hyperexcitability promotes microglial activation. Together, these observations suggest that amygdala microglia convert nociceptive and affective states into a systemic inflammatory milieu that speeds epigenetic aging.

Mechanistic Model

1. Nociceptive input or fear‑related stimuli activate CRF⁺ neurons in the central amygdala.
2. Activated CRF⁺ neurons release CRF, which binds receptors on resident microglia, shifting them to a primed phenotype.
3. Primed microglia upregulate NLRP3, pro‑caspase‑1 and pro‑IL‑1β.
4. A secondary hit (e.g., low‑level ATP release from stressed neurons) triggers inflammasome assembly, caspase‑1 cleavage and secretion of mature IL‑1β.
5. IL‑1β enters the bloodstream, stimulates hepatic acute‑phase proteins and promotes NF‑κB signaling in peripheral immune cells, raising circulating inflammatory markers (IL‑6, TNF‑α, CRP).
6. Chronic low‑grade inflammation drives DNA methyltransferase dysregulation, accelerating epigenetic age clocks.

Predictions

• Individuals with low pressure or heat pain thresholds will show higher central amygdala microglial activation (measured by TSPO‑PET) than high‑tolerance peers, independent of self‑reported pain duration.
• Plasma IL‑1β and caspase‑1 activity will correlate inversely with pain thresholds and positively with epigenetic age acceleration (ΔAge = DNAmAge – chronological age).
• Pharmacological inhibition of microglial activation (e.g., minocycline) or NLRP3 blockade (e.g., MCC950) will normalize pain thresholds and attenuate epigenetic age acceleration in a chronic pain model, without altering corticosterone levels.
• Genetic ablation of CRF receptors specifically on amygdala microglia will break the link between low pain tolerance and inflammasome activation, preserving epigenetic youth despite persistent nociceptive input.

Experimental Design

Human cohort: Recruit 120 adults aged 40‑70, stratify by pressure pain threshold (low vs high). Perform quantitative sensory testing, TSPO‑PET of the amygdala, fasting plasma IL‑1β, caspase‑1 activity, and epigenetic clock analysis (Horvath, PhenoAge, GrimAge). Use mediation analysis to test whether amygdala microglial binding mediates the relationship between pain threshold and ΔAge.

Animal model: Induce neuropathic pain in rats via spared nerve injury. Measure paw withdrawal thresholds, central amygdala TSPO signal, NLRP3 inflammasome components, and plasma IL‑1β. Treat groups with minocycline, MCC950, or vehicle. Assess epigenetic age using rat‑specific DNAm clocks after 4 weeks. Include a group with CRISPR‑mediated CRF receptor knockdown in amygdala microglia.

Potential Confounds and Controls

Control for analgesic medication, BMI, smoking, and comorbidities. Include a stress‑only cohort (restraint pain‑free) to isolate HPA‑axis effects. Verify that plasma IL‑6 and TNF‑α do not fully mediate the pain‑threshold–ΔAge relationship, confirming the specificity of the inflammasome axis.

If microglial inflammasome activation does not correlate with pain thresholds or epigenetic age, or if blocking this pathway fails to modify either phenotype, the hypothesis would be falsified.